2022 ESMO Blockbuster Drug Latest Research Progress Announced! Innovent Biologics, Hehuang Pharmaceutical and others appeared at the event

The European Society of Oncology (ESMO) Congress is one of the world's largest oncology events, bringing together important research results

2022 ESMO

and Huang Medicine

The fruquintinib Phase III FRESCO-2 study published positive results

FRESCO-2 study

The FRESCO-2 study is a global multicenter clinical trial conducted in the United States, Europe, Japan and Australia to evaluate the efficacy and safety

In terms of safety, the safety profile of fruquintinib in the FRESCO-2 study is consistent

Fruquintinib is a potent oral small molecule inhibitor of highly selective vascular endothelial growth factor receptor (VEGFR) 1, 2 and 3, developed

In September 2018, fruquintinib was approved by the State Food and Drug Administration for the treatment of patients with metastatic colorectal cancer (mCRC) who had previously received fluorouracil, oxaliplatin and irinotecan-based chemotherapy, as well as patients who had previously received or were not eligible for anti-vascular endothelial growth factor (VEGF) therapy and anti-epidermal growth factor receptor (RAS wild type) therapy, trade name: iYote

2022 ESMO

Cinda Bio

Daboshu and Dayou's Phase III ORIENT-31 study achieved PFS improvement

ORIENT-31 study

The ORIENT-31 study is a randomized, double-blind, multicenter Phase III clinical study

The ORIENT-31 study is the first prospective, double-blind Phase III study in the world to confirm that the PD-1 immune checkpoint inhibitor ± bevacizumab combined with chemotherapy significantly prolongs PFS in nonsquamous NSCLC populations with EGFR-TKI treatment

Daboshu is an innovative PD-1 inhibitor drug jointly developed by Innovent Biopharma and Eli Lilly Pharmaceuticals, which was approved in China on December 24, 2018, and more than 20 clinical studies are currently underway, with 6 indications

2022 ESMO

Corning Jerry

Latest clinical data on KN046 and KN026

KN026+KN046 for HER2+GC/GEJC

The trial was an open and multicenter Phase II clinical trial enrolling 31 patients with HER2-positive locally advanced non-resectable or metastatic GC/GEJ who had not previously received systemic therapy, and were given 30 mg/kg Q3W of KN026 (loading doses on day 1 and 8 of the first cycle) plus 5 mg/kg Q3W of KN046 until disease progression or toxic intolerance developed

KN046+ platinum first-line treatment NSCLC followed up for two years

The median follow-up time for this open-label and multicentre Phase II clinical trial was 23.

KN046 is used for first-line platinum-containing dual-agent chemotherapy for metastatic NSCLCs that have failed

The clinical trial enrolled 64 patients with metastatic NSCLC who failed first-line platinum-containing dual-agent chemotherapy and did not receive PD-(L)1 immune checkpoint inhibitors, with a median follow-up time of 21.

KN046 treats metastatic NSCLCs that have failed treatment with previous EGFR-TKIs

The phase II one-arm clinical trial enrolled 26 patients with EGFR-sensitive mutations who had previously failed treatment with EGFR-TKIs and had not received platinum-containing chemotherapy, and were given KN046 (5 mg/kg Q3W) plus chemotherapy (500 mg/m2 Q3W pemetrexed and AUC=5 Q3W carboplatin) until disease progression, toxicity intolerance, and other discontinuation criteria

KN046 is a PD-L1/CTLA-4 bispecific antibody independently developed by Corning Jereh, which is composed of the fusion of CTLA-4 and PD-L1 monodomain antibodies with different mechanisms, which can target the tumor microenvironment enriched with high PD-L1 expression and clear Treg

KN026 is a targeted HER2 bispecific antibody drug independently developed by Corning Jereh, which has been approved by the State Food and Drug Administration and indd approval by the FDA, and is carrying out a number of Phase I/II clinical studies in China and the United States, showing good initial efficacy